347P - Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Central Nervous System Malignancies
Presenter Estela Pineda
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors E. Pineda1, M. Martinez-Garcia2, A. Estival3, M. Gil-Gil4, S. Del Barco5, O. Gallego6, E. Verger7, J. Marruecos8, R. Fuentes8, J. Craven-Bartle Lamote de Grigno9, C. Mesía10, N. García11, F. Alameda12, J.M. Velarde13, T. Pujol14, L. Oleaga14, C. Carrato15, J. Capellades2, S. Villà16, C. Balana11
  • 1Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2Department Of Medical Oncology, University Hospital del Mar, Barcelona/ES
  • 3Department Of Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 4Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 5Medical Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona/ES
  • 6Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 7Radiotherapy, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 8Radiation Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona/ES
  • 9Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 10Medical Oncology, Thoracic Oncology Unit, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 11Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona/ES
  • 12Pathology, University Hospital del Mar, Barcelona/ES
  • 13Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, http://cpaper.ctimeetingtech.com/images/_common_blue/48x48/black_arrow.png - Badalona/ES
  • 14Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 15Pathology, Hospital universitari germans trias i pujol, 08916 - Badalona/ES
  • 16Radiation Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES

Abstract

Background

Prognosis of GBM pts is still poor with a median survival of 15 months; however a small fraction survives more than 30 months, defined in our study as long term survivors (LTS-30).

Methods

We performed a multicenter retrospective and prospective study of newly GBM pts treated with the Stupp Regimen. In the present sub-study we analyze clinical characteristics and molecular factors in LTS-30 compared with pts surviving less than 30 months, including the MGMT and the IDH1 status.

Results

From 2005 to 2014, 432 GBM pts treated with the Stupp Regimen were included with a median progression free survival (mPFS) of 8 months (m) and a median overall survival (mOS) of 14 months, of which 66 (15.3%) were LTS-30, with a mPFS of 24 m and a mOS of 41 m. In this population median karnofsky (KPS) was better (90% vs 80%) with less patients with KPS inferior to 70% (1.9% vs 13.9%; p = 0.006), and median age was also lower (58 vs 62 years) with more pts ≤50 years (34.8% vs 18.3%; p = 0.003). Median OS in patients with IDH1 mutation was 30 m vs 16 m (p = 0.005). Methylated MGMT and mutated IDH1 were significantly more frequent in LTS-30, 75% vs 40.8% (p 

Conclusions

Identifying potential LTS in GBM might be a meaningful endpoint in order to establish the best therapeutic strategy. In our study, methylation status of MGMT is the only independent prognostic factor of LTS-30 in GBM pts treated with Stupp regimen. As expected, patients with LTS-30 are younger with better KPS and with more frequent IDH1 mutation.

Clinical trial identification

Marato Project: 665/C/2013.

Legal entity responsible for the study

IGTP, IDIBELL, Fundacio Parc Salut Mar, Fundacio Clinic

Funding

Marato Project: 665/C/2013

Disclosure

All authors have declared no conflicts of interest.